Focused On-demand Library for Gamma-aminobutyric acid receptor-associated protein-like 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P60520

UPID:

GBRL2_HUMAN

Alternative names:

GABA(A) receptor-associated protein-like 2; Ganglioside expression factor 2; General protein transport factor p16; Golgi-associated ATPase enhancer of 16 kDa; MAP1 light chain 3-related protein

Alternative UPACC:

P60520; O08765; Q6FG91; Q9DCP8; Q9UQF7

Background:

Gamma-aminobutyric acid receptor-associated protein-like 2 (GABARAPL2) plays a pivotal role in cellular processes, including intra-Golgi traffic and autophagy. By modulating NSF activity and SNAREs activation, GABARAPL2 ensures efficient intra-Golgi transport. Its involvement in autophagy and mitophagy is crucial for maintaining cellular energy balance and preventing excess ROS production. The protein is essential for autophagosome maturation, highlighting its significance in cellular homeostasis.

Therapeutic significance:

Understanding the role of Gamma-aminobutyric acid receptor-associated protein-like 2 could open doors to potential therapeutic strategies. Its critical function in autophagy and mitophagy, processes vital for cellular health and energy regulation, positions GABARAPL2 as a key target in developing treatments for diseases where these processes are dysregulated.